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Abstract
Background: Relatively little is known about the relationship between psychosocial crises and treatment
costs for persons with schizophrenia. This naturalistic prospective study assessed the association of recent
crises with mental health treatment costs among persons receiving treatment for schizophrenia.
Methods: Data were drawn from a large multi-site, non-interventional study of schizophrenia patients in
the United States, conducted between 1997 and 2003. Participants were treated at mental health
treatment systems, including the Department of Veterans Affairs (VA) hospitals, community mental health
centers, community and state hospitals, and university health care service systems. Total costs over a 1-
year period for mental health services and component costs (psychiatric hospitalizations, antipsychotic
medications, other psychotropic medications, day treatment, emergency psychiatric services,
psychosocial/rehabilitation group therapy, individual therapy, medication management, and case
management) were calculated for 1557 patients with complete medical information. Direct mental health
treatment costs for patients who had experienced 1 or more of 5 recent crisis events were compared to
propensity-matched samples of persons who had not experienced a crisis event. The 5 non-mutually
exclusive crisis event subgroups were: suicide attempt in the past 4 weeks (n = 18), psychiatric
hospitalization in the past 6 months (n = 240), arrest in the past 6 months (n = 56), violent behaviors in
the past 4 weeks (n = 62), and diagnosis of a co-occurring substance use disorder (n = 413).
Results: Across all 5 categories of crisis events, patients who had a recent crisis had higher average annual
mental health treatment costs than patients in propensity-score matched comparison samples. Average
annual mental health treatment costs were significantly higher for persons who attempted suicide
($46,024), followed by persons with psychiatric hospitalization in the past 6 months ($37,329), persons
with prior arrests ($31,081), and persons with violent behaviors ($18,778). Total cost was not significantly
higher for those with co-occurring substance use disorder ($19,034).
Conclusion: Recent crises, particularly suicide attempts, psychiatric hospitalizations, and criminal arrests,
are predictive of higher mental health treatment costs in schizophrenia patients.
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Background
Schizophrenia is among the most costly of all mental ill-
nesses, with an estimated annual per person direct treat-
ment cost that is approximately 2-fold higher than the
cost of major depression and more than 4-fold higher
than any anxiety disorder [1]. In addition to genetic fac-
tors [2] and medication adherence [3-5], various clinical
and demographic factors are associated with higher risk of
relapse and hospitalization, events that are predictive of
higher costs [6]. These factors include male gender, lower
educational level, unemployment, higher illness chronic-
ity, higher frequency of alcohol consumption, co-occur-
ring alcohol and substance abuse, a history of depression
and/or suicide attempts, a history of violence and/or
arrests, and recent hospitalization [7-10]. The positive
association of these factors with mental health treatment
costs suggests that persons who are more vulnerable to cri-
ses (i.e., personal life events typically associated with an
acute societal intervention) have higher treatment costs
than persons who are less vulnerable to these events.
The relationship between crisis events and treatment costs
has not been well-studied. Most prior studies of costs are
based on administrative data that provide relatively little
information about vulnerabilities and recent crises [11].
Information about the relationship of crises to costs is
essential for accurate risk adjustment, the process of
assigning capitation rates for enrollees of public and pri-
vate health insurance plans. Capitation rates that are set
too low provide plans and HMOs insufficient incentive to
treat high-risk, high cost patients [12-14]. Information on
the effect of crisis events is particularly valuable at a time
when there are concerted efforts to decrease patient hospi-
talization and manage various types of psychiatric crises
in the community. In the United States, for example, the
length of hospital stay has gradually declined in the past
10 years [15], attesting to economic and policy-driven
pressures to reduce psychiatric hospitalizations. Informa-
tion about crisis events has also clinical utility in usual
care settings, where it may help identify more vulnerable
patients with more complex illness trajectories who
require specialized interventions and better coordination
with other social agencies, including the criminal justice
system.
Most prospective longitudinal data do not enable the
study of whether patients diagnosed with schizophrenia
who have experienced a recent crisis incur higher direct
mental health costs compared to patients who have not
experienced a crisis. However, the availability of compre-
hensive clinical, functional and economic data from a
large 3-year prospective non-interventional observational
study of persons treated for schizophrenia in the United
States provided the opportunity to address this topic in
some detail. The objective of the current investigation was
to assess the relationship between recent crisis events and
direct annual mental health costs in patients diagnosed
with schizophrenia spectrum disorders in clinical practice
settings. The crisis events examined included (1) suicide
attempt, (2) psychiatric hospitalization, (3) arrest, (4)
violent behavior, and (5) substance use disorder. Five sep-
arate propensity score analyses were performed (one for
each crisis event) to evaluate the relationship between
each crisis event and cost when compared to the group of
individuals who did not experience that specific crisis
event.
Methods
Study design
Data used in the current analysis are from the U.S. Schiz-
ophrenia Care and Assessment Program (US-SCAP), a
prospective, non-interventional, non-randomized, 3-year
observational study of more than 2300 persons with
schizophrenia. The data used in the current analysis con-
sist of the first full year of data available for each patient
in the study. The goal of the US-SCAP was to examine the
relationship of clinical and treatment variables with out-
comes of persons diagnosed with schizophrenia-spectrum
disorders who were receiving mental health care in outpa-
tient and inpatient settings at 6 treatment sites. The study,
conducted between July 1997 and September 2003,
enrolled a total of 2327 patients at 6 health care sites cho-
sen to provide a diverse patient sample in terms of geog-
raphy, ethnicity, and clinical setting (e.g., university and
community mental health centers, Veterans Affairs (VA)
hospitals, and community and state hospitals). Sites were
only included in the study if they offered open and unre-
stricted formulary access to all available antipsychotics
and were not relying on any algorithms for treatment deci-
sion-making. The study protocol was reviewed and
approved by the Institutional Review Board (IRB) at each
site prior to study initiation, and written informed con-
sent was obtained from all participants.
A detailed description of study design and methods are
provided in previous publications [16-18]. Briefly, US-
SCAP study enrollment was offered to all patients who
were 18 years or older who had a DSM-IV diagnosis of
schizophrenia, schizoaffective, or schizophreniform dis-
order. Patients were enrolled regardless of psychiatric or
medical comorbidity, use of concomitant medications, or
presence of behavioral problems (criminal or otherwise).
The goal was to obtain the broadest and most representa-
tive sample of schizophrenia-spectrum patients seen in
clinical practice settings.
For the purposes of the current cost analysis, a subgroup
of US-SCAP enrollees (n = 1557; 67%) was identified who
had a full year of information available on mental health
resource utilization. If patients had >1 year of mental
health resource information, the patient's earliest year was
used in the current analysis.BMC Psychiatry 2008, 8:72 http://www.biomedcentral.com/1471-244X/8/72
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Five crisis subgroups were defined based on the presence
of any one of the following events at the start of the 1-year
observation period: (1) a suicide attempt in 4 weeks prior
to the baseline assessment per patient self report; (2) a
psychiatric hospitalization in the 6 months prior to base-
line per medical records; (3) an arrest in the 6 months
prior to baseline per patient self report; (4) violent behav-
ior in the 4 weeks prior to baseline per patient self report;
and (5) a diagnosis of substance use disorder, based on
medical record, which occurred at any time during the
study period.
Measures
At study entry, patients completed a semi-structured inter-
view, during which information about psychiatric history
and background characteristics was collected. Patients'
medical records were systematically abstracted every 6
months by examiners, trained and certified by the contract
research organization, using a medical record abstraction
form developed for this study that summarized mental
health resource utilization during the preceding 6
months. Patients were queried about use of medical and
psychiatric services outside of their usual treatment site.
Study staff members regularly obtained medical records
from treatment sites mentioned by patients. At 6-month
intervals, patients also completed the SCAP-Health Ques-
tionnaire (SCAP-HQ [19]), a personal interview that
includes questions on recent drug and alcohol use (in the
past 12 months), suicide attempt (in the past 4 weeks),
arrests (in the past 6 months), and violent behavior (in
the past 4 weeks). At 1-year intervals, clinical assessments
of psychiatric symptoms, medication side-effects, and
functioning were completed by trained clinicians.
Assessment of costs
The total annual direct costs were calculated as the sum of
the following component charges: medication costs,
including antipsychotics and other psychotropics (the
cost of antipsychotics was based on Average Wholesale
Price discounted by 15% for atypical antipsychotics);
costs of psychiatric hospitalization (based on the actual
charges); and costs of other mental health services (based
on Relative Value Units [RVUs; 20,21] developed from
management information systems (MIS) data at each site
to help address variations across sites in available infor-
mation about resource types, costs, and durations). The
costs of other mental health services included the follow-
ing cost components: emergency services, day treatment,
outpatient medication management by a physician, indi-
vidual outpatient therapy, outpatient psychosocial group
interventions, and case management.
Statistical analyses
For comparisons of baseline characteristics, t-tests were
used for continuous variables and Mantel-Haenszel chi-
square tests for categorical variables. In order to correct for
potential bias not attributable to membership in a crisis
event subgroup, the propensity score method was used to
balance the crisis event versus non-crisis event subgroups.
The variables selected a priori for calculating the logit score
using the propensity method were: age at enrollment, gen-
der, race, illness duration, comorbid affective disorder,
comorbid substance use, comorbid personality disorder,
diagnosis of mental retardation, insurance status, inpa-
tient status at the beginning of the 1-year observation
period, site, and days from July 1 1997 to the beginning
of the study. Substance use was not used in the propensity
score model when substance use was being analyzed as
the crisis event, and inpatient status was not used in the
propensity score model when costs associated with recent
psychiatric hospitalizations were estimated.
The propensity score-adjusted bootstrapping method ana-
lyzed mean differences of costs between each crisis event
and non-crisis event group by first calculating the logit
score for each patient based on the above adjustments.
Five bins of logit scores were then created for each crisis
event group. The bootstrap resampling method was per-
formed by randomly selecting an equal size of sample
from each of the 10 bins (5 bins for each treatment) into
1 group and calculating the total cost difference between
the 2 treatment groups. The above steps were then
repeated 1000 times, generating a total of 1000 data
points' distribution for testing the null hypothesis using
2-tailed p-values [22]. The propensity score-adjusted
bootstrapping method was also used to test the mean dif-
ferences of costs for the 2 high level crisis event groups:
patients with 2 or more crisis-event variables and patients
with 3 or more crisis-event variables. This method accom-
modates the distributional and correlational properties of
the data [23]. In addition to mean total cost and cost of
psychiatric hospitalization per patient for the index year,
we also calculated the mean annual length of psychiatric
hospital stay and the mean number of psychiatric hospital
admissions per crisis event category. This information
aimed at clarifying which type of crisis made a significant
and unique contribution to increased costs due to hospi-
talization, the costliest component in the treatment of
schizophrenia. SAS version 8 was used to perform all sta-
tistical analyses, with all effects tested at a 2-sided α level
of 0.05 [24].
Results
The total sample used in the cost analysis consisted of the
1557 patients (Table 1) for whom there were at least 1
year of complete medical information during the 3-year
study period. For the cost analysis sample, the typical
patient was between 30 and 50 years of age, with at least
a 10-year history of illness. Almost all (94.9%) of patients
were taking an antipsychotic drug at the time of enroll-BMC Psychiatry 2008, 8:72 http://www.biomedcentral.com/1471-244X/8/72
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ment; 38.3% were also taking an antidepressant, and
31.0% were also taking a mood stabilizer.
Participants who had incomplete medical information for
the purpose of costs calculations (N = 770) were excluded
from this study. The excluded patients were similar to the
analysis sample (N = 1557) in terms of gender (male: 63%
vs. 60%; p = .489), but were significantly younger (40.8 ±
11.4 vs. 42.4 ± 11.1 years; p < .01) and were less likely to
be African-American (32% vs. 38%), but more likely to be
Hispanic (17% vs. 13%) or Caucasian (51% or 49%; over-
all p = .013). Compared to the 1557 retained subjects, the
excluded group was also more likely to have been hospi-
talized in the prior 6 months (15.4% vs 25.2%, respec-
tively), to be arrested in the prior 6 months (3.8% vs
10.1%), to manifest violent behaviors in the past 4 weeks
(4.2% vs 8.4%) and attempt suicide in the past 4 weeks
(1.2% vs 3.8%), but had a similar proportion of persons
with substance abuse diagnosis (36.1% vs 29.5%). The
excluded group may have experienced a greater interface
with the criminal justice system (e.g., jails), thus less likely
to have complete mental health information in the
present study.
The mean 1-year mental health treatment costs per patient
totaled $16,098 (Table 2). Te two largest costs were psy-
chotropic medication (30%) and hospitalization (29%;
Figure 1). The remaining 6 cost component categories
comprised 48% of the total cost, with none contributing
more than 10% (Figure 1). Among the hospitalized partic-
ipants, the correlation between hospitalization costs and
total mental health treatment costs during the index year
was high (r = .987, p < .001), reflecting the fact that hos-
pitalization is the core driver of total costs.
Sorting patients into crisis event categories yielded 5 over-
lapping subgroups. The largest subgroups were co-occur-
ring substance use disorder (n = 413) and hospitalized in
the past 6 months (n = 240), followed by violent in the
past 4 weeks (n = 62), arrested in the past 6 months (n =
56), and attempted suicide in the past 4 weeks (n = 18).
Prior to formal matching, each of the crisis event sub-
groups was not substantially different from each other on
most baseline demographic and clinical characteristics
(Table 3). The typical patient was most likely to be a male
(~61%) between the ages of 30 and 50 years. As expected,
the proportion of males was somewhat higher in the sub-
group who had been arrested in the past 6 months (80%)
and the subgroup with comorbid substance abuse (74%).
Though the sample size was small (N = 18), the subgroup
who had recently attempted suicide was younger (mean
age, 34 years), more likely to be female (61%), and more
likely to have a depressive component, with a mean
MADRS score of 31, and a diagnosis of schizoaffective dis-
order (50%; Table 3).
The five crisis event categories were not mutually exclusive
(Table 4), with highest levels of overlap between sub-
stance use disorder, arrest, suicide attempt and violent
behavior. A substantial proportion (46.4%) of those with
arrest, with suicide attempt (44.4%), and with violent
behaviors (41.9%) had also a diagnosis of substance
abuse. While 21.1% of those with substance abuse diag-
Table 1: Demographic and clinical characteristics of patients at 
enrollment
Characteristic N = 1557
N%
Male 948 60.9
Single, never married 938 60.5
Ethnicity
White 762 48.9
Black 589 37.8
Other 206 13.2
Health insurance
Medicaid/Medicare 1243 81.2
Department of Veteran Affairs 97 6.3
Private insurance 70 4.6
Other coverage 16 1.1
No health insurance 104 6.8
Educational attainment, high school or less 1047 67.9
Mean SD
Age, years 42.4 11.1
Age at illness onset, years 20.7 8.9
MADRS total score 13.6 10.2
PANSS total score 69.1 18.4
Medication days in the 6 months prior to enrollment
Atypical antipsychotic 96.5 87
Typical antipsychotic 90.1 87
Antidepressant 59.1 81.8
Mood stabilizer 46.7 77.3
Other psychotropic 75.5 84.9
PANSS, Positive and Negative Symptoms of Schizophrenia scale
MADRS, Montgomery-Åsberg Depression Rating Scale
Table 2: Mean 1-year per patient total cost and cost components 
(n = 1557)
Cost component Mean Cost ($) 
(standard deviation)
Total annual cost 16,098 (24,791)
Medications 4,817 (3,858)
Antipsychotics 3,770 (3,244)
Other psychotropics 1,047 (1,313)
Psychiatric hospitalizations 4,687 (23,536)
Day Treatment 1,571 (3,734)
Emergency Services 84 (196)
Psychosocial group therapy 1,478 (3,126)
Medication management 1,187 (1,331)
Individual therapy 1,267 (1,826)
Case management 1,006 (958)BMC Psychiatry 2008, 8:72 http://www.biomedcentral.com/1471-244X/8/72
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nosis were hospitalized, about a third (36.3%) of the hos-
pitalized had co-occurring diagnosis of substance abuse.
Furthermore, participants with substance use disorders
had the lowest mean annual number of hospitalization
days (25.5) and a relatively low mean annual number of
psychiatric admissions (0.7).
The 1-year hospitalization and total 1-year mental health
treatment costs were calculated for each crisis event sub-
group, and compared, using a propensity score adjusted
bootstrap re-sampling method (repeated 1000 times), to
the non-crisis event subgroup. The results of this analysis
(summarized in Table 5) found significantly higher mean
1-year hospitalization costs, and total mental health costs,
for each crisis event subgroup except comorbid substance
abuse. The mean total annual mental health cost for the
subgroup who had experienced no crisis event was
$11,739 per patient. The mean total mental health cost
for patients with at least 1 crisis event was $22,704 per
patient, with the highest cost observed in the subgroup of
patients who attempted suicide, followed by patients with
a recent psychiatric hospitalization, arrest, violent behav-
ior, and those with comorbid substance use disorder
(Table 5). Of the patients (n = 619) who qualified for
inclusion in at least 1 crisis event subgroup, 30.9% had
experienced only one crisis event, 8.9% had experienced 2
or more crisis events, and 1.9% had experienced 3 or more
events. The presence of ≥2 and ≥3 crisis events was associ-
ated with a significant and step-wise increase in both 1-
year hospitalization and total 1-year mental health costs
compared to the costs in the non-crisis event subgroup,
reflecting a high mean number of hospitalization days
(72.7 and 101.1 days, respectively) and a high mean
number of hospital admissions (1.7 and 2.7, respectively)
(Table 6).
Discussion
Previous research has identified various clinical variables
as significant predictors of relapse and hospitalization in
patients diagnosed with schizophrenia. The current study
extends these findings by providing, for the first time,
information on the annual mental health costs associated
with experiencing specific crisis events. The use of com-
prehensive assessments in a prospective naturalistic study
with valid and reliable instruments enabled the identifica-
tion of individuals who had experienced specific crisis
events, and the systematic collection of resource utiliza-
tion data for different types of mental health services.
Given the large and diverse sample of schizophrenia
patients analyzed and the prospective, naturalistic design,
the findings of the study are likely to be applicable to
patients with schizophrenia treated in large systems of
care across the United States.
Although 60.2% of the participants did not report experi-
encing a crisis event, 39.8% of the patients did, with
30.9% of all participants meeting only one crisis event cri-
terion, 8.9% meeting 2 or more criteria, and about 2%
meeting three or more criteria. Thus, the base rate for
experiencing a crisis event was not low.
As hypothesized, patients experiencing a crisis event that
took place (or at least started) before the 1-year observa-
tion period accounted for a preponderance of the total
mental health costs during that period. Furthermore, a
disproportionate contribution to increased mental health
costs was made by the subgroup who reported experienc-
ing 2 or more crisis events. The per patient mean total
annual mental health cost for the non-crisis event sub-
group was $11,739, while patients who reported at least 1
crisis event had a per patient mean of $22,704. (Note that
the mean total costs shown in Table 5 for each crisis event
subgroup are higher, because some of the individuals in
each group may have experienced 1 or more additional
crisis events.)
The highest annual per patient total mental health cost
was in the subgroup of patients who attempted suicide,
followed by patients with a recent psychiatric hospitaliza-
tion. In the current investigation, patients with a concur-
rent substance use disorder did not appear to have
significantly higher total mental health costs compared to
those without a substance use disorder. This is an unex-
pected finding since substance abuse has previously been
reported to be a predictor of medication nonadherence
[25,26], which, in turn, is often reported to be a highly sig-
Mental health cost components as a proportion of total  annual mental health costs Figure 1
Mental health cost components as a proportion of 
total annual mental health costs. Of the 1-year per 
patient total mental health treatment cost of $16,098, the 
largest single contributor was the cost of hospitalization 
(29%), followed by antipsychotic medication (23%). Each of 
the remaining 6 cost component categories contributed less 
than 10% to the total.
Antipsychotics
23%
Other 
Psychotropics
7%
Hospitalization
29%
Day Treatment
10%
Emergency 
Services
1%
Group Therapy
9%
Medication 
Management
7%
Individual 
Therapy
8%
Case Management
6%BMC Psychiatry 2008, 8:72 http://www.biomedcentral.com/1471-244X/8/72
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Table 3: Characteristics of patients in each crisis event subgroup prior to propensity score matching
Crisis events
Characteristic Hospitalized in 
past 6 months
Arrested in past 
6 months
Violent in past 4 
weeks
Concurrent 
substance abuse
Attempted 
suicide in past 4 
weeks
Non-crisis event 
subgroup
Sample sizes
Yes 240 56 62 413 18 938
No 1317 1469 1463 1144 1507 619
Age, years
Yes 39 (10.3) 38.9 (9.7) 40.7 (10.0) 39.9 (9.8) 33.8 (11.0) 43.9 (11.4)
No 43 (11.2) 42.6 (11.1) 42.5 (11.1) 43.2 (11.4) 42.6 (11.0) 40 (10.2)
Age of Illness 
onset, yrs
Yes 19.8 (8.6) 19.4 (6.3) 18.9 (7.8) 19.4 (8.3) 16.4 (5.8) 21.4 (9.1)
No 20.8 (8.9) 20.8 (9.0) 20.8 (9.0) 21.1 (9.0) 20.8 (9.0) 19.6 (8.5)
MADRS total 
score
Yes 15.6 (11.0) 14.0 (10.5) 19.9 (12.0) 13.5 (10.8) 30.9 (12.5) 13.1 (9.8)
No 13.2 (10.0) 13.5 (10.1) 13.3 (10.0) 13.6 (10.0) 13.4 (10.0) 14.3 (10.8)
PANSS total score
Yes 73.9 (18.4) 71.1 (15.7) 72.0 (18.8) 69.6 (19.1) 86.7 (16.9) 68.0 (17.8)
No 68.2 (18.2) 69.1 (18.5) 69.0 (18.4) 68.9 (18.0) 69.0 (18.3) 70.8 (19.0)
Medication days in 
6 mos. prior to 
enrollment
Atypicals
Yes 96.2 (82.9) 61.7 (81.1) 71.2 (84.4) 91.0 (87.0) 89.3 (82.2) 98.6 (87.5)
No 96.6 (87.7) 97.7 (86.9) 97.4 (86.9) 98.5 (86.9) 96.5 (87.0) 93.4 (86.2)
Typicals
Yes 72.2 (82.0) 95.9 (82.9) 98.4 (88.8) 98.1 (86.5) 60.9 (80.8) 90.3 (87.6)
No 93. 4 (87.4) 89.8 (87.1) 89.7 (86.9) 87.2 (86.9) 90.4 (87.0) 89.7 (85.8)
Antidepressant
Yes 54.2 (78.9) 55.1 (81.0) 71.2 (84.4) 53.1 (80.0) 74.7 (86.6) 61.3 (82.6)
No 60(82.3) 59.6 (82.0) 58.9 (81.8) 61.3 (82.4) 59.2 (81.9) 55.9 (80.6)
Mood stabilizer
Yes 64.1 (82.0) 41.3 (74.3) 46.4 (77.1) 38.7 (71.7) 61.0 (84.1) 45.5 (77.3)
No 43.5 (76.0) 47.0 (77.5) 46.8 (77.4) 49.6 (79.1) 46.6 (77.3) 48.6 (77.4)
Other 
psychotropic
Yes 71.0 (80.5) 63.8 (79.9) 99.1 (82.5) 79.3 (85.4) 36.1 (63.3) 74.1 (85.5)
No 76.4 (85.7) 75.7 (85.0) 74.3 (84.8) 74.2 (84.8) 75.7 (85.0) 77.7 (84.2)
Male, N (%)
Yes 142 (59.2) 45 (80.4) 38 (61.3) 304 (73.6) 7 (38.9) 527 (56.2)
No 806 (61.2) 882 (60.0) 889 (60.8) 644 (56.3) 920 (61.0) 421 (68.0)
Single, N (%)
Yes 149 (62.3) 46 (82.0) 26 (41.9) 262 (63.8) 11 (61.1) 549 (58.8)
No 789 (60.2) 871 (59.6) 891 (61.2) 676 (59.4) 906 (60.4) 389 (63.2)
Diagnosis, N (%)
Schizophrenia
Yes 119 (49.6) 33 (58.9) 32 (51.6) 257 (62.2) 9 (50.0) 620 (66.1)
No 861 (65.4) 926 (63.0) 927 (63.4) 723 (63.2) 950 (63.0) 360 (58.2)
Schizoaffective
Yes 103 (42.9) 17 (30.4) 28 (45.2) 125 (30.3) 9 (50.0) 282 (30.1)
No 393 (29.8) 469 (31.9) 458 (31.3) 371 (32.4) 477 (31.7) 214 (34.6)
Other 
psychotic
Yes 19 (7.9) 6 (10.7) 2 (3.2) 31 (7.5) 0 38 (4.1)
No 65 (4.9) 77 (5.2) 81 (5.5) 53 (4.6) 83 (5.5) 46 (7.4)
Means (standard deviations) unless otherwise specified. Patients may belong to more than one subgroup. Yes = with event; No = without event.
PANSS, Positive and Negative Symptoms of Schizophrenia scale
MADRS, Montgomery-Åsberg Depression Rating Scale
Atypicals = atypical antipsychotics
Typicals = typical antipsychoticsBMC Psychiatry 2008, 8:72 http://www.biomedcentral.com/1471-244X/8/72
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nificant predictor of future relapse and hospitalization
[27-29]. One possible explanation is suggested by recent
data from the Clinical Antipsychotic Trials in Intervention
Effectiveness (CATIE) study which found that substance
abuse was a marker for higher psychosocial functioning in
schizophrenia [30]. Another possibility is that some of the
substance abusing participants – especially those with
prior arrests and violent behaviors- had more extensive
interface with the criminal justice system (e.g., jails), thus
some of their costs may have shifted from the mental
health to the criminal justice system. In addition, nonad-
herence with medication may also underlie the higher
costs incurred by patients in the other crisis event catego-
ries, since nonadherence with antipsychotic medication
was previously found to be associated not only with psy-
chiatric hospitalizations but also with a higher risk of vio-
lent behaviors, arrests and suicide attempts [29]. While
detecting ongoing medication nonadherence may be dif-
ficult and challenging in usual care settings, the occur-
rence of a crisis event is apt to be more readily identifiable,
thus serve as a clinical marker of patients' greater vulnera-
bility from a clinical and functional perspective. This may
turn out to be a convenient way of targeting subsets of
patients with different illness profiles (e.g., with different
diagnostic characteristics, illness trajectories, or vulnera-
bility factors) and effectively treating individuals who
experience crisis events.
Cost differences among patients who experience a crisis
event appeared to be primarily driven by the cost of psy-
chiatric hospitalization, with a strong and significant cor-
relation (r = .99) between hospitalization cost and total
annual mental health costs. In the current analysis, hospi-
talization comprised, however, only 29% of the total
annual mental health costs, while antipsychotic medica-
tion comprised 23%. This finding is inconsistent with
prior research in which the cost attributed to hospitaliza-
tion was of larger proportion- about 50%–80% – of the
total cost [31,32]. The reason for the inconsistency is
unclear. The relatively low percentage attributed to hospi-
talization may reflect the way that costs were calculated in
the present study. Specifically, the cost of psychiatric hos-
pitalization was based on actual charges while the cost of
antipsychotics was based on Average Wholesale Price dis-
counted by 15% and the cost of other non-hospitalization
mental health services was based on Relative Value Units.
It is possible, therefore, that the methods of estimating
non-hospitalization costs led to their overestimation rela-
tive to hospitalization cost. Furthermore, the relative cost
contribution of hospitalization and antipsychotic medica-
tion to overall total direct costs would be substantially
lower in the current study if non-psychiatric medical costs
and direct non-health care costs had been available for
analysis.
Study limitations
The study has important limitations which deserve to be
highlighted. First, the criteria for several of the crisis event
subgroups (attempted suicide, arrested, violent) were
based on a patient-reported measure, not on objective
data. It should also be noted that substance abuse is not,
strictly speaking, a discrete event, but an ongoing condi-
tion. Second, the sample sizes for several of the crisis event
subgroups were small, most notably for the "attempted
suicide" group. The appropriateness of the propensity
score adjusted bootstrap re-sampling method with such
small sample sizes may be questionable. Third, some hos-
pitalizations may have been underreported since stays in
state psychiatric hospitals may not have been reported by
all patients, and such hospitalizations would have been
Table 4: Proportion of participants in each crisis event category and degree of overlap between categories
Hospitalized in 
prior 6 months
Arrested in 
previous 6 months
Violent behavior in 
previous 4 weeks
Concurrent 
substance abuse 
diagnosis
Attempted suicide 
in past 4 weeks
Hospitalized in 
prior 6 months 
(N = 240)
__ 22 (9.2%) 17 (7.1%) 87 (36.3%) 11 (4.6%)
Arrested in 
previous 6 months 
(N = 56)
22 (39.3%) __ 5 (8.9%) 26 (46.4%) 1 (1.8%)
Violent behavior in 
previous 4 weeks 
(N = 62)
17 (27.4%) 5 (8.1%) __ 26 (41.9%) 2 (3.2%)
Concurrent 
substance abuse 
diagnosis 
(N = 413)
87 (21.1%) 26 (6.6%) 26 (6.6%) __ 8 (2.0%)
Attempted suicide 
in past 4 weeks 
(N = 18)
11 (61.1%) 1 (5.6%) 2 (11.1%) 8 (44.4%) __BMC Psychiatry 2008, 8:72 http://www.biomedcentral.com/1471-244X/8/72
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missed by most of the MIS systems. Fourth, emergency
department visits may have also be significantly underre-
ported, since they would not have been captured by MIS
or by medical record in most cases. This might help to
explain why the estimate of emergency department costs
was negligible in the current study. Fifth, an estimation
bias may have occurred in the calculation of medication
costs using average wholesale price (AWP; discounted by
15% for atypical antipsychotics). The AWP may not reflect
variations in medication costs and greater discount rates
across different health care systems. A final limitation is
that the estimates reported in this paper are for mental
health costs only and do not include non-psychiatric
medical costs or direct non-health care costs (e.g., patient
involvement in the criminal justice system, use of home-
less shelters) – the latter alone have been estimated at $9.3
billion per year [2]. The omission of these cost categories
has likely resulted, in the current analysis, in an overesti-
mate of the relative contribution of some cost categories.
Future cost studies should include data on direct non-
health care costs, especially since the mental health cost
burden is being increasingly shifted to the criminal justice
system.
Conclusion
Mental health costs of treating patients diagnosed with
schizophrenia and related disorders are highly heteroge-
neous. Patients who experience crisis events, particularly
Table 5: Mean 1-year total costs, hospitalization costs and hospitalization parameters for patients with and without specific crisis event 
categories
Patients with event Mean 1-year total 
mental health cost 
per patient
Mean 1-year cost of 
psych hospitalization 
per patient
Mean number of 
days hospitalized
Mean number of 
hospital 
admissions
N%
Hospitalization in 
previous 6 months
Yes 240 15.4 $37,329 ** $23,962 ** 73.3 1.9
No 1317 84.6 $12,229 $1,175 4.8 0.3
Arrested in 
previous 6 months
Yes 56 3.7 $31,081 * $20,334 * 55.8 1.1
No 1469 96.3 $15,654 $4,180 14.1 0.5
Violent behavior in 
previous 4 weeks
Yes 62 4.1 $18,778 ** $7,416 ** 29.6 1.3
No 1463 95.9 $16,113 $4,661 15.1 0.5
Concurrent 
substance abuse 
disorder
Yes 413 26.5 $19,034 $7,455 25.5 0.7
No 1144 73.5 $15,038 $3,688 11.7 0.5
Attempted suicide 
in past 4 weeks
Yes 18 1.2 $46,024 ** $30,080 ** 61.8 1.3
No 1507 98.8 $15,865 $4,471 15.1 0.5
* P < .05; ** P < .01; P values compare non-crisis event group cost ("no") vs. crisis event group cost ("yes") for each event.
Table 6: Mean 1-year costs for patients with and without specific number of crisis event categories
Number of types of crisis events
None One only Two or more Three or more
Patients with event, N (%) 938 (60.2%) 481 (30.9%) 138 (8.9%) 29 (1.9%)
Mean 1-year cost of hospitalization per patient $830 $6,912 * $23,149 * $33,199 *
Mean 1-year total mental health cost per patient $11,739 $19,066 * $35,385 * $44,599 *
Mean number of days hospitalized 3.7 21.8 72.7 101.1
Mean number of hospital admissions 0.2 0.8 1.7 2.7
* P < .01; P values based on non-crisis event group vs. each category: patients with only one type of crisis event, two or more types of events, and 
three of more types of crisis events.BMC Psychiatry 2008, 8:72 http://www.biomedcentral.com/1471-244X/8/72
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those with a recent suicide attempt or psychiatric hospital-
ization, tend to incur the highest annual mental health
costs, driven primarily by the cost of psychiatric hospital-
ization. Patients involved in the criminal justice system
(with prior arrest) also accrue relatively high costs within
the mental health delivery system. More prospective
research, in usual care settings, is needed to identify high
risk patients and to determine which interventions are the
most cost effective.
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